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Abstract: Recovery from ebolavirus infection in humans is associated with the development 
of both cell-mediated and humoral immune responses. According to recent studies, 
individuals that did not survive infection with ebolaviruses appear to have lacked a robust 
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adaptive immune response and the expression of several early innate response markers. 
However, a comprehensive protective immune profile has yet to be described. Here, we 
examine cellular memory immune responses among survivors of two separate Ebolavirus 
outbreaks (EVDs) due to Sudan virus (SUDV) infection in Uganda—Gulu 2000–2001 and 
Kibaale 2012. Freshly collected blood samples were stimulated with inactivated SUDV, as 
well as with recombinant SUDV or Ebola virus (EBOV) GP (GP1–649). In addition, ELISA 
and plaque reduction neutralization assays were performed to determine anti-SUDV IgG 
titers and neutralization capacity. Cytokine expression was measured in whole blood cultures 
in response to SUDV and SUDV GP stimulation in both survivor pools, demonstrating recall 
responses that indicate immune memory. Cytokine responses between groups were similar 
but had distinct differences. Neutralizing, SUDV-specific IgG activity against irradiated 
SUDV and SUDV recombinant proteins were detected in both survivor cohorts. Furthermore, 
humoral and cell-mediated crossreactivity to EBOV and EBOV recombinant GP1–649 was 
observed in both cohorts. In conclusion, immune responses in both groups of survivors 
demonstrate persistent recognition of relevant antigens, albeit larger cohorts are required in 
order to reach greater statistical significance. The differing cytokine responses between Gulu 
and Kibaale outbreak survivors suggests that each outbreak may not yield identical memory 
responses and promotes the merits of studying the immune responses among outbreaks of the 
same virus. Finally, our demonstration of cross-reactive immune recognition suggests that 
there is potential for developing cross-protective vaccines for ebolaviruses. 
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1. Introduction 
Ebolaviruses are members of the Filoviridae family, which contains a single-stranded, negative-sense 
RNA genome encoding seven genes [1]. These genes encode a nucleoprotein (NP), viral proteins VP35 
and VP40, a glycoprotein (GP), viral proteins VP30 and VP24 and the viral RNA-dependent RNA 
polymerase (L) [2,3]. Among the different proteins expressed by ebolaviruses, the surface glycoprotein, 
GP, plays a central role in viral attachment, entry, cytotoxicity, as well as induces both cellular and 
humoral immune responses, and activates pro-inflammatory pathways [3,4]. 
In July 2012, an Ebola virus outbreak (EVD) occurred in the Kibaale district, Uganda. EVD can be 
caused by four distinct ebolaviruses: Bundibugyo, Ebola, Sudan, and Taï Forest virus. Laboratory tests 
during the outbreak confirmed Sudan virus (SUDV) infection in eleven patients resulting in four deaths. 
This ebolavirus, first discovered in 1976, reemerged in the Gulu district of Uganda in 2000–2001 and 
was responsible for 425 confirmed infections and 224 deaths [5,6]. 
During the last decade, various studies that examine the pathogenesis of ebolavirus infection in 
humans have indicated that recovery is largely dependent on the development of both cell-mediated 
immunity and an effective humoral immune response [4,7]. Ebolavirus infection triggers the release of 
cytokines and chemokines, including interleukin (IL)-1β, IL-6, IL-8, IL-15 and interferon-γ (IFNγ) [8]. 
In addition, evidence from studies that examined survivors and asymptomatic cases, demonstrated the 
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presence of significant levels of virus-specific IgM and IgG titers associated with a temporary, early and 
strong inflammatory response [9–12]. However, a comprehensive protective immune profile has yet to 
be described. 
Here, we investigate the presence of cellular memory immune responses in human survivors of SUDV 
from two different EVD outbreaks in Uganda using a whole blood cytokine stimulation assay. Samples 
were collected on-site from five of the seven survivors of the 2012 EVD outbreak due to SUDV infection 
that occurred in Kibaale, and were compared to six survivors of the 2000 EVD disease outbreak due to 
SUDV infection in the Gulu district, which were previously shown to contain raised humoral and cellular 
immunity [12]. To this end, freshly collected heparinized blood samples were added to preloaded 
reaction tubes containing specific stimulators; post-stimulation plasma supernatants were then isolated 
and analyzed. Specific stimulation conditions included inactivated SUDV, recombinant SUDV GP1–649 
and recombinant Ebola virus (EBOV) GP1–649. Post-stimulation analytes included IL-1β, IL-2, IL-5,  
IL-10, IFNγ and TNFα. Additionally, SUDV-specific IgG levels and SUDV neutralization capacity were 
also assessed. 
2. Materials and Methods 
2.1. Study Design 
Subjects included confirmed survivors from the SUDV-caused EVD outbreaks of 2000–2001 and 
2012 in Gulu and Kibaale districts, Uganda, respectively [5,13], and healthy local community members 
of each district that were not infected. Study participants were unrelated (except two isolated samples 
from Kibaale) and, according to outbreak medical records, infection progression and prognosis did not 
necessarily exhibit genetic predisposition.  
2.2. Ethics Statement 
The study was approved by the Helsinki committees of the Uganda Virus Research Institute in 
Entebbe, Uganda (reference number GC/127/13/01/15), Soroka Hospital, Beer-sheva, Israel (protocol 
number 0263-13-SOR) and the Ugandan National Council for Science and Technology (UNCST) 
(registration number HS1332). A written informed consent was translated for and signed by each subject; 
a personal health questionnaire was completed for each subject at the time of blood collection. 
2.3. Sample Collection 
Whole blood samples were obtained from individuals by routine antecubital venipuncture. Samples 
were directly aspirated into sterile vacutainers containing freeze-dried sodium heparin (final heparin 
concentration 14.3 units/mL, Becton Dickinson, Franklin Lakes, NJ, USA) and kept at 4 °C until assayed 
within a uniform timeframe. 
2.4. Antigens and Stimulants 
Stimulation assay antigens included irradiated, sucrose gradient purified, SUDV-gul (Sudan virus /H. 
sapiens-tc/UGA/Gulu-808892) and purified recombinant (His-tagged) SUDV-gul or EBOV (Ebola 
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virus/H. sapiens-tc/COD/1995/Kikwit) GP viral polypeptide, residues 1 to 649 (GP1–649) [14]. A lectin 
from Phaseolus vulgaris Leucoagglutinin, PHA-L, (Sigma-Aldrich, Israel) was used as positive control 
for cell stimulation. For ELISA assays, irradiated SUDV-gul, purified recombinant (His-tagged)  
SUDV-gul GP1–649, and total 293T cell lysate that expressed a given recombinant SUDV-gul protein 
(NP, VP30, VP35 and VP40) were used as the capture antigens. Construction of the recombinant SUDV 
viral gene expression vectors and production of irradiated SUDV and EBOV have been described 
previously [15]. Cell lysates from cultures not expressing recombinant viral protein were used as control. 
Irradiated, sucrose gradient purified, EBOV and purified recombinant (His-tagged) EBOV GP1–649 were 
also used as capture antigens for cross reactivity-assessing ELISA. 
2.5. Internal Control Sera 
Internal human control sera for ELISA were previously described [14]. Positive controls for the 
detection of SUDV GP1–649 and EBOV GP1–649 included murine monoclonal antibodies 3C10 and 6D8 
that target the SUDV and EBOV GP, respectively [16]. 
2.6. Specific IgG Detection Assays 
The levels of circulating anti-SUDV, anti-SUDV recombinant viral proteins, anti-EBOV and  
anti-EBOV GP1–649 antibodies were determined by chemiluminescence ELISA, as previously  
described [14] with minor modifications. A 100 μL volume of total cell lysate expressing SUDV Flag 
tag, recombinant viral protein (antigen) or cell lysate (mock antigen) at a concentration of 15 μg/well,  
or 2 μg/mL of purified SUDV or EBOV GP1–649, or whole virus SUDV or EBOV antigens in phosphate 
buffered saline (PBS) without Mg+2 and Ca+2, pH 7.4, was passively adsorbed onto ELISA plates 
(MaxiSorp, Nunc™, Thermo Fisher Scientific Inc., Waltham, MA, USA) overnight in a humidified 
chamber at 4 °C. After incubation, plates were washed three times with 0.1% (v/v) Tween-20  
(Sigma-Aldrich Israel Ltd., Rehovot, Israel) in PBS; the same washing procedure followed each 
subsequent stage of the assay. Plates were then blocked with 10% (w/v) skim milk (Merck, Darmstadt, 
Germany) in PBS. After incubation at 37 °C for 1 h, plates were washed and triplicate 100 μL volumes 
of each tested serum and controls at 1:400 dilution were added to wells containing the recombinant viral 
proteins and mock antigens. Further controls, including an anti-FLAG murine monoclonal antibody, 
goat anti-SUDV serum and murine anti-SUDV and EBOV GP1–649 monoclonal antibodies were added 
at a dilution of 1:1000, 1:3000 and 1:1000, respectively. After incubation for 1 h at 37 °C, plates were 
washed, and a volume of 100 μL goat anti-human IgG HRP conjugate (1:10,000, Santa Cruz 
Biotechnology, Dallas, TX, USA) was added to wells. For murine anti-Flag, anti-GP1–649, and goat  
anti-SUDV antiserum controls, a volume of 100 μL goat anti-mouse and donkey anti-goat IgG HRP 
conjugate (1:10,000, Santa Cruz Biotechnology) were added to the wells, respectively. After incubation, 
plates were washed, and 40 μL of oxidizing reagent (H2O2) and enhanced luminal reagent solutions 
(NEL105 chemiluminescence reagent kit) were loaded at a 1:1 ratio. Optical absorbance was measured 
using a standard luminometer (Infinite F200, TECAN, Männedorf, Switzerland). 
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2.7. Normalization of Raw Data and Selection of Cut-off Values 
Calculation of signal to noise (S/N) values, for anti-SUDV recombinant proteins NP, VP30, VP35, 
and VP40 specific IgG, was performed as previously described [14]. The cutoff value for IgG positive 
immunoreactivity was determined with a control set of negative sera and ten-fold stratified  
cross-validation analysis [17]. For the purified SUDV, EBOV and GP1–649 proteins, raw ELISA data 
were converted to percent positivity (PP) of a high internal control antibody. Calculation of PP values, 
as well as the cutoff value, was performed as previously described [18]. Normalization of cytokine 
expression levels in whole blood stimulation assays was performed by removing background 
(unstimulated expression) for each respective stimulated sample. 
2.8. Plaque Reduction Neutralization Test 
Plaque reduction neutralization assays (PRNT50) were performed as previously described [19]. Six 
ten-fold serial dilutions of serum were mixed with 100 plaque-forming units of SUDV or EBOV at 37 °C 
for 1 h in the presence or absence of 5% guinea pig complement (Cedarlane, Burlington, NC, USA). 
Following incubation, 125 μL of the reaction mix was loaded onto Vero cell monolayers in 96 well plates 
(Costar, Cambridge, MA, USA). Cells were overlaid with agarose-based medium and a second overlay 
containing 5% neutral red was added 8 days later. Plates were then incubated at 37 °C, with 5% CO2 
over-night, and plaques were counted the following day. Neutralization titers were determined to be the 
last dilution of serum that reduced the number of plaques by 50% compared with control wells. Plaque 
reduction neutralization assays were performed in the BSL-4 lab of USAMRIID (Fort Detrick, 
Frederick, MD, USA). 
2.9. Whole Blood Stimulation from Ebolavirus Survivors and Healthy Volunteers 
Whole blood stimulation was performed as previously described [20] with minor modifications. 
Heparinized venous blood obtained from SUDV survivors and healthy volunteers was aliquoted into  
12 × 75 mm snap-cap polypropylene tubes under sterile conditions. Each blood sample from both 
survivor and control subjects was diluted 1:4 in RPMI-1640 supplemented with 5% FCS. Irradiated 
SUDV antigen (10 μg/mL), SUDV GP1–649 (50 μg/mL), or EBOV GP1–649 (50 μg/mL), were added to 
individual aliquots (1.0 mL final vol.), in duplicates, and the cultures were incubated at 37 °C/5% CO2 
for 22 h. PHA-L (10 μg/mL) was used as a positive control for cell activation, negative control consisted 
of a non-stimulated culture. Following incubation, culture supernatants were aspirated, transferred to 
new 1.5 mL tubes and frozen at –70 °C until further processing. 
2.10. Cytokine Detection Using Q-Plex™ ELISA-Based Chemiluminescent Assay 
Levels of human cytokines were detected using Q-Plex technology (Quansys Biosciences, Logan, 
UT, USA) according to manufacturer's instructions. Briefly, 30 μL of each sample (duplicate) was 
diluted 1:2 in diluent buffer, and a total volume of 50 μL of diluted sample and control standards was 
added to a 96-well v-bottom binding plate. Plates were then incubated for 1 h on a shaker at room temperature 
in the dark. Following incubation, plates were washed and a volume of 50 μL of detection mix was added 
to each well, and incubated for 1 h. Next, plates were washed and a volume of 50 μL streptavidin HRP 
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was added to each well and incubated for additional 15 min. Finally, plates were washed and a volume 
of 50 μL substrate mix was added to each well. Readouts were obtained with a Quansys Imager  
(Quansys Biosciences, Logan, UT, USA) and results analyzed using the Q-View Software program 
(Quansys Biosciences). 
2.11. Statistical Analysis 
Statistical analyses were performed using GraphPad Prism software 6.01 (GraphPad Software, Inc., 
La Jolla, CA, USA). Differences in cytokine values between study groups were assessed by analysis of 
variants (ANOVA) and Wilcoxon rank sum test; p-values represent 2-sided p-values (0.05),  
and p-values < 0.05 were considered statistically significant. 
3. Results 
3.1. Cohorts and Blood Samples 
Whole blood samples were obtained from a total of twenty donors. Of these, eleven were collected 
from survivors of the 2000–2001 and 2012 EVD outbreaks in Gulu (n = 6 infected and n = 4  
non-infected) and Kibaale (n = 5 infected and n = 5 non-infected), respectively. Samples were collected 
from the Gulu cohort and Kibaale cohort approximately 12 years and 1 year post infection, respectively. 
Samples from healthy personnel (Soroka Hospital, Beer-Sheva, Israel) were used to compare baseline 
immune response levels (n = 3, data served for background reduction and are not shown). All subjects 
reported lack of autoimmune diseases, cancer and past hospitalizations that are unrelated to EVD (Tables 
S1 and S2). Survivors were hospitalized for 10–30 days during the outbreak and reported uniform 
treatment and post-recovery symptoms during and following SUDV infection (not shown). 
3.2. Humoral Response Profiles against SUDV Proteins 
Kibaale survivors had mixed immune-reactivity against SUDV-derived recombinant viral proteins: 
all reacted against VP40, four against NP, GP1–649 and SUDV-gul whole virus, three against VP30 and 
two against VP35 (Table 1). 
Serum collected from all five survivors demonstrated neutralization activity against live SUDV. As 
expected, no neutralization or immune reactivity was observed in the non-infected control group. 
Samples from survivors of the Gulu 2000–20001 EVD outbreak were previously analyzed [12] and 
were retested as comparison against Kibaale survivors. All survivors in this study displayed positive  
immune-reactivity against SUDV, as well as to recombinant viral proteins NP, VP30 and GP1–649 (Table 2). 
Four individuals displayed serum reactivity to VP40, and one against VP35. Neutralization assay 
results demonstrated positive SUDV neutralization in five samples. No neutralization or reactivity to 
inactivated virus or recombinant proteins was observed in the non-infected control group. 
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Table 1. Serology and neutralization of Kibaale survivors. Summary of ELISA 
immunoreactivity, and PRNT50, in human survivor sera from Kibaale (S1–S5) and non-infected 
controls (N1–N5), against the different viral recombinant proteins of SUDV and the whole 
viral antigen. 
 Serology PRNT50 
 VP30 VP35 VP40 NP GP1–649 
1 SUDV Whole Ag SUDV 
S-1 +++ - ++ +++ +++ +++ +++ 
S-2 ++ - +++ +++ +++ +++ +++ 
S-3 - + ++ ++ ++ ++ ++ 
S-4 - - +++ - - - + 
S-5 ++ + ++ +++ +++ +++ +++ 
N-1 - - - - - - - 
N-2 - - - - - - - 
N-3 - - - - - - - 
N-4 - - - - - - - 
N-5 - - - - - - - 
¹ A purified recombinant protein containing the 649 amino terminal amino acid of SUDV GP without the  
trans-membrane domain. S—Ebola survivors, N—Non-infected control ELISA and neutralization assays  
results were divided into low (+), medium (++) and strong (+++) immunoreactivity or neutralization capability. 
For ELISA: (+)—(Lower than 2x cut off value), (++)—(2x cut off value – 4x cut off value), (+++)—(Greater 
than 4x cut off value). For neutralization assay (PRNT50): (+)—(Neutralizes at 1:20 dilution), (++)—(Neutralizes 
at 1:40 dilution), (+++)—(Neutralizes at greater than 1:80 dilution). 
Table 2. Serology and neutralization of Gulu survivors. Summary of ELISA immunoreactivity, 
and PRNT50, in human survivor sera from Gulu (S1–S6), and non-infected controls (N1–N4), 
against the different viral recombinant proteins of SUDV and the whole viral antigen. 
 Serology PRNT50 
 VP30 VP35 VP40 NP 
GP1–649 
1 
SUDV Whole Ag SUDV 
S-1 ++ - + +++ +++ +++ +++ 
S-2 + - + +++ +++ +++ + 
S-3 + + - +++ +++ ++ +++ 
S-4 +++ - - + +++ +++ +++ 
S-5 ++ - + +++ +++ ++ - 
S-6 +++ - +++ +++ +++ +++ ++ 
N-1 - - - - - - - 
N-2 - - - - - - - 
N-3 - - - - - - - 
N-4 - - - - - - - 
¹ A purified recombinant protein containing the 649 amino terminal amino acid of SUDV GP without the  
trans-membrane domain. S—Ebola survivors, N—Non-infected control ELISA and neutralization assays 
results were divided into low (+), medium (++) and strong (+++) immunoreactivity or neutralization capability. 
For ELISA: (+)—(Lower than 2x cut off value), (++)—(2x cut off value—4x cut off value), (+++)—(Greater 
than 4x cut off value). For neutralization assay (PRNT50): (+)—(Neutralizes at 1:20 dilution),  
(++)—(Neutralizes at 1:40 dilution), (+++)—(Neutralizes at greater than 1:80 dilution). 
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3.3. SUDV-Induced Cytokine Levels in Whole Blood Stimulation Assay 
To identify markers of cell-mediated immune responses to SUDV, cytokine levels were determined 
following whole blood stimulation using SUDV, recombinant SUDV GP1–649, or recombinant EBOV 
GP1–649. PHA-L stimulation was used as a positive control for immune cell responses and non-stimulated 
samples served as baseline controls. SUDV survivors from Kibaale and Gulu exhibited equivalent baseline 
levels of cytokines compared to healthy non-infected controls (data not shown). PHA-L stimulation control 
exhibited a positive response in all tested groups, including healthy non-infected controls (data not shown). 
Stimulation of whole blood samples with SUDV or SUDV GP elicited cytokine secretion that was 
markedly elevated relative to resting cultures as well as uninfected controls (Figure 1). 
 
Figure 1. Cytokine levels comparison between SUDV-Gul whole antigen (A); and GP1–649 
(B) stimulation and unstimulated whole blood from Kibaale (1-year) and Gulu (12-year) 
ebolavirus survivors and non-infected controls (CT). Non-infected controls of Kibaale and 
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Gulu are presented as average results since there were no significant changes between the 
two groups (Data not shown). Cytokine levels were measured in the plasma supernatants of 
samples following whole blood stimulation and resting state. Mean ± SEM, * p < 0.05. 
One year after the outbreak, Kibaale survivors demonstrated a significant increase in IL-1β, IL-10, and 
TNFα, and elevated expression levels of IL-2, IL-5 and IFNγ. Cytokine levels in the 12-year post-outbreak 
Gulu survivors demonstrated a stronger response than that observed in Kibaale survivors with a significant 
increase in IL-1β, IL-2, IL-5, IFNγ and TNFα levels, and elevated expression levels of IL-10. No significant 
change was observed in non-infected control group (CT). 
Comparison of cytokine levels between SUDV Kibaale and Gulu survivors and non-infected controls 
(Figure 2), displayed a significant high cytokine response in samples of Gulu survivors compared to 
those of Kibaale and non-infected control groups following both SUDV and SUDV GP1–649 stimulation, 
with the exception of IL-10 expression levels. 
 
Figure 2. Cytokine levels following SUDV/Gul whole antigen (A) and GP1–649 (B) 
stimulation of whole blood from Kibaale (1-year) and Gulu (12-year) ebolavirus survivors 
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and non-infected controls (CT). Cytokine levels were measured in the plasma supernatants 
of samples following whole blood stimulation. Normalization of cytokine expression levels 
was performed by reducing the background (unstimulated value) of each individual 
stimulated (SUDV/Gul whole antigen or GP1–649) sample. Non-infected controls of Kibaale 
and Gulu are presented as average results since there were no significant changes between 
the two groups of controls (Data not shown). Mean ± SEM, * p < 0.05. 
3.4. Humoral, Cell-Mediated and Neutralization Cross Reactivity to EBOV GP1–649 in SUDV Survivors 
In the Kibaale group, three individuals exhibited various degrees of cross-serological reactivity 
towards EBOV GP1–649 (Table 3) with two of those individuals showing cross reactivity towards EBOV 
whole virus. Results of survivors from Gulu group displayed a similar degree of crossreactivity to 
EBOV; three out of six individuals demonstrated cross reactivity towards EBOV GP1–649, and one 
displayed positive cross reactivity towards EBOV whole virus. Uninfected control serum exhibited no 
reactivity to EBOV or EBOV GP (Table 3). 
Table 3. Serology and neutralization for EBOV cross-reactivity. Summary of ELISA 
immunoreactivity, and PRNT50, in human survivor sera from Kibaale (1-year) and Gulu  
(12-year) outbreaks, and non-infected controls, against the viral recombinant protein GP 
(GP1–649) of EBOV and the whole viral antigen. 
Kibaale Group Gulu Group 
 EBOV Whole Ag EBOV GP1–649 PRNT50  EBOV Whole Ag EBOV GP1–649 PRNT50 
S-1 - + - S-1 - +++ - 
S-2 +++ +++ - S-2 - - - 
S-3 - - - S-3 - + - 
S-4 - - - S-4 - - - 
S-5 + ++ - S-5 - - - 
N-1 - - - S-6 ++ ++ - 
N-2 - - - N-1 - - - 
N-3 - - - N-2 - - - 
N-4 - - - N-3 - - - 
N-5 - - - N-4 - - - 
S—Ebola survivors, N—Non-infected control ELISA results were divided into low (+), medium (++) and 
strong (+++) immunoreactivity: (+)—(Lower than 2x cut off value), (++)—(2x cut off value—4x cut off value), 
(+++)—(Greater than 4x cut off value). For neutralization assay (PRNT50): (+)—(Neutralizes at 1:20 dilution), 
(++)—(Neutralizes at 1:40 dilution), (+++)—(Neutralizes at greater than 1:80 dilution). 
In vitro whole blood assays were performed using EBOV GP1–649 to determine if SUDV survivors 
had cross-reactive memory cellular immunity with EBOV proteins. As demonstrated in Figure 3, highly 
inducible cytokines were detected in survivors and controls. Significant elevation in IL-1β, IL-2, IL-5, 
IFNγ and TNFα was observed in the Gulu cohort in response to EBOV GP1–649 stimulation. 
Significant elevation of IL-2, IL-5, IL-10 and TNFα expression levels was observed in the Kibaale 
survivor group and non-infected controls. Comparison between SUDV survivor groups and non-infected 
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controls (Figure 4) demonstrated a significantly higher cytokine cross reactive response mainly in 
samples from the Gulu group of survivors. 
 
Figure 3. Cytokine levels comparison between EBOV GP1–649 stimulation and unstimulated 
whole blood from Kibaale (1-year) and Gulu (12-year) ebolavirus survivors and non-infected 
controls (CT). Cytokine levels were measured in the plasma supernatants of samples 
following whole blood stimulation. Non-infected controls of Kibaale and Gulu are presented 
as average results since there were no significant changes between the two groups of controls 
(Data not shown). Mean ± SEM, * p < 0.05. 
 
Figure 4. Cytokine levels following EBOV GP1–649 stimulation of whole blood from Kibaale 
(1-year) and Gulu (12-year) ebolavirus survivors and non-infected controls (CT). Cytokine 
levels were measured in the plasma supernatants of samples following whole blood 
stimulation. Normalization of cytokine expression levels was performed by reducing the 
background (unstimulated value) of each individual stimulated (EBOV GP1–649) sample. 
Non-infected controls of Kibaale and Gulu are presented as average results since there were 
no significant changes between the two groups (Data not shown). Mean ± SEM, * p < 0.05. 




Filoviruses cause a severe hemorrhagic fever in humans resulting in a progressive and overwhelming 
disease [3]. Work in nonhuman primates and other smaller animal models demonstrates that adaptive 
immunity contributes to protection against ebolavirus infection [21,22] and that this immune protection 
is associated with the development of both cellular and humoral immunity [23–27]. 
In the work described herein, we present results of a study designed to investigate and compare 
markers of cellular and humoral memory immune responses in two distinct SUDV survivor cohorts. 
Assessing these parameters is essential for understanding immune parameters associated with protection 
against ebolavirus infection and to facilitate the development of effective vaccines and therapeutics. 
Using samples collected from SUDV survivors of the Kibaale outbreak in 2012, and the Gulu outbreak 
in 2000–2001 [12], the following parameters were compared: IgG immunoreactivity, neutralization 
capacity and cytokine expression levels following in vitro whole blood stimulation. The data were also 
compared to samples from non-infected individuals in both districts and to healthy off-site volunteers. 
The results of our study demonstrate that significant differences in cytokine expression levels and profile 
exist between SUDV survivor cohorts groups and non-infected controls. The immune responses in 
SUDV survivors from Kibaale were analyzed one year after the outbreak, whereas the Gulu outbreak 
survivors’ responses were determined 11 years after the outbreak. Despite the fact that the Gulu outbreak 
occurred over a decade prior to the outbreak in Kibaale, it is striking that Gulu survivors have more 
robust memory immune responses, as measured by cytokine production. Whether or not these 
differences can be attributed to varying environmental factors or supportive care given during  
the outbreak remains a point of speculation. Some cytokines, such as TNFα, IL-2, IFNγ and IL-5 are 
associated with T cell responses and therefore suggest T cell memory responses, but some cytokines 
associated with innate, pro-inflammatory immune responses were also detected. This is perhaps explained 
by a potential ability of the antigens used in this assay to stimulate innate immune cells, or could be a 
nonspecific activation event due to T cell cytokine production. Though this was not a focus in these assays, 
it would be intriguing if the recombinantly produced SUDV GP was inherently immuno-stimulatory. 
Nonetheless, the presence of T cell-associated cytokines vouches for an antigen-specific memory 
immune response. 
Interestingly, the whole blood stimulation data reveals a significantly higher level of IL-10 expression 
in the Kibaale outbreak survivors. Although it remains speculative, this finding may suggest  
anti-inflammatory immunity among Kibaale outbreak survivors in contrast to those from Gulu, or may 
also reflect distinct time periods from infection. 
The in vitro stimulation assay, while providing a clear picture of cellular responses, has several 
limitations. Whole blood inducible expression levels during stimulation were measured during one time 
point from the addition of stimulants to cells, and activation was performed using the SUDV/Gul isolate. 
Some cytokines require specific time frames for optimal peak detection, and might also display variation 
in response to particular stimulants. However, the undertaking of such an in-depth study under local 
conditions was not feasible at the point of sample collection; the maximal magnitude of sample replicates 
and added control conditions was reached in the present study design. Although the use of SUDV/Gul 
for activation during our assay limits the comparison between the two groups of survivors, it is unlikely 
that antigen isolate variation would be responsible for the significant difference in cytokine responses as 
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genomic analysis between Gulu and Kibaale isolates reveals 99% sequence identity [5], and the humoral 
immune response presented in this work demonstrates robust recognition in both groups of survivors. 
Humoral and cell-mediated cross reactivity against EBOV GP1–649 and EBOV demonstrated that 
SUDV survivor sera from both cohorts, regardless of the time post infection, reacted against EBOV 
whole virus and EBOV GP1–649. However, while survivor sera demonstrated positive recognition 
according to an ELISA, both Gulu and Kibaale groups lacked cross-neutralization capacity against EBOV. 
In vitro whole blood stimulation assays using EBOV GP1–649 demonstrated positive cross reactivity mainly 
in the Gulu cohort as compared to the Kibaale cohort. These high cross reactive profiles may reflect a 
stronger cellular immunity developed over the years. However, the elevated cytokine cross-stimulation 
profile could also result from differences in genetic background, geographic location, or the limited number 
of samples tested in the present work. Nevertheless, the overall humoral- and cell-mediated cross reactivity 
results identified in the present study suggest that a spectrum of immunity persists in long-recovered Sudan 
virus or EVD survivors, which is broader than may have been previously perceived. 
The results of our study also have implications for vaccine development. SUDV survivors appeared 
to have developed a strong IgG immune response against the viral protein GP, and this viral protein 
evoked production of high cytokine expression levels following whole blood stimulation. These results 
are in agreement with previous studies [3,28,29], supporting the fact that activation of humoral and 
cellular neutralizing immunity could be achieved using vaccines based on the viral GP alone. 
Overall, the data presented in this study is essential for providing further insights regarding the nature 
of the native human humoral and cellular immune response following EBOV infection. Such data will 
facilitate the development of optimized vaccines and immune therapeutics for filovirus infections. 
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